Analyst Price Targets — IFRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 13, 2026 11:27 am | Strong Buy | Raymond James | $9.00 | $2.54 | TheFly | InflaRx upgraded to Strong Buy from Outperform at Raymond James |
| December 3, 2025 11:10 am | — | Leerink Partners | $2.00 | $0.99 | TheFly | InflaRx downgraded to Market Perform from Outperform at Leerink |
| May 29, 2025 8:50 am | — | Raymond James | $2.00 | $0.85 | TheFly | InflaRx downgraded to Outperform from Strong Buy at Raymond James |
| January 6, 2023 4:32 am | — | H.C. Wainwright | $6.00 | $2.92 | Benzinga | HC Wainwright & Co. Maintains Buy on InflaRx, Lowers Price Target to $6 |
Latest News for IFRX
Jena, Germany, Aug. 20, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in two investor conferences in September 2026. Details are as follows:
Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as planned Initiated feasibility assessment for broadened strategy for AAV in Europe Reported new pre-clinical data supporting the safety and differentiation of izicopan as a next-generation oral inhibitor of C5aR Pharmacokinetic (PK) bridging study in China expected to start late this year,…
Jena, Germany, July 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its second quarter 2026 financial and operating results on August 6, 2026, before the market opens. No conference call is planned.
Kamada (NASDAQ: KMDA - Get Free Report) and InflaRx (NASDAQ: IFRX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk. Institutional and Insider Ownership 20.4% of Kamada shares are
Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has initiated this assessment given the recommendation of the European Medicines Agency's (EMA)…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IFRX.
U.S. House Trading
No House trades found for IFRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.